LinkedIn Icon Twitter Icon
March 19-21, 2019 | Boston, MA

Speakers

Expand/Collapse

Sarah McWhirter
Director – Sting Program
Aduro Biotech

Day One

March 20, 2019

16.00 | Discover how Utilisation of the STING pathway has Bolstered the Effectiveness of PD-L1

Jeremy Graff
Chief Scientific Officer & Senior Vice President - Research
Biothera

Day Two

March 21, 2019

14.45 | Panel Discussion – How Can We Sort Through the Huge Number of Trials that are Currently Active?

08.40 | Harnessing the Innate Immune System

Jochem Gokelmeijer
Associate Director
Bristol-Myers Squibb

Mark Paris
Director - Translational Applications
Mitra Biotech

Day One

March 20, 2019

12.00 | A Clinically-Predictive Ex-Vivo Tumor Modelling Platform for Drug Discovery and Development

Mithun Khattar
Scientist & Immuno-oncology lead
Takeda

Workshop A

MARCH 19, 2019

09.00 | Pre-Clinical Development Challenges in Checkpoint Modulators and IO Combinations

Osama Rahma
Assistant Professor
Dana-Faber Cancer Center

Patrick Holder
Scientist
Genentech

Day Two

March 21, 2019

09.40 | Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

Paul Moore
Vice President - Cell Biology & Immunology
Macrogenics

Day Two

March 21, 2019

14.15 | PD-1-Based Bispecific Antibody Therapies

13.15 | PD-1-Based Bispecific Antibody Therapies

Raphael Clynes
Vice President - Translational Biology
Xencor

Day Two

March 21, 2019

09.10 | T Cell Engagers, Checkpoints and Cytokines to Broaden Immune Responses to Cancer

Shanthi Ganesh
Associate Director
Dicerna Pharmaceuticals

Stephen Doberstein
Senior Vice President - Research, Chief Scientific Officer, Chief Research & Development Officer
Nektar Therapeutics

Day One

March 20, 2019

11.30 | Supercharging the Tumor Microenvironment: Lessons from NKTR-214 and Opdivo

Viviana Cremasco
Investigator
Novartis

Weiyi Peng
Instructor
MD Anderson Cancer Center

Wim Van Schooten
Chief Scientific Officer
Teneobio

John Burke
President, Chief Executive Officer & Co-founder
Applied Biomath

Day One

March 20, 2019

09.40 | Model Aided Drug Invention Case Study: GITR-mediated T cell dynamics in Mouse Tumor Micro Environment

Paul Rennert
President and Chief Scientific Officer
Aleta Biotherapeutics

Day One

March 20, 2019

09.10 | Establishing a New Set of Biological Goals for Checkpoint Inhibitors and IO Combinations

Mark Yore
Manager of Corporate Development
Jounce Therapeutics

Day One

March 20, 2019

08.40 | Navigating the complex ICI-IO landscape – Recent updates and Future Challenges

Amy-Jo Casbon
Immunotherapy & Oncology Scientist
Amgen Inc.

Bei Wang
Staff Scientist
Regeneron

Day One

March 20, 2019

16.30 | Combining PD-1 with GITR to Rescue CD8+ T Cell Dysfunction

Beth Trehu
Chief Medical Officer
Jounce Therapeutics

Day One

March 20, 2019

12.30 | Lessons Learned from a Clinical Trial Targeting ICOS

Bruno Osterwalder
Senior Vice President
BO Consulting

Day Two

March 21, 2019

14.45 | Panel Discussion – How Can We Sort Through the Huge Number of Trials that are Currently Active?

Catherine Sabatos-Peyton
Director
Novartis

Day Two

March 21, 2019

09.40 | Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

Cedric Dos Santos
Principal Scientist - Heme, Oncology, Clinical Biomarkers & Therapeutic Areas Lead
Amgen Inc.

Eva Vanamee
Chief Scientific Officer
FusionBio

Day Two

March 21, 2019

09.40 | Panel Discussion: Mind the Gap - Considering New Targets from Biological Rationale to Therapeutic Protein Delivery

Hans Van Eenemann
Executive Vice President Antibody Research
Aduro Biotech

Day Two

March 21, 2019

13.45 | Innate Myeloid-Cell Inhibition: Explore the Capability of CD-27 Novel Checkpoint-Modulation as an Inhibitor